By effectively inhibiting KIF20A, Paprotrain disrupts the autocrine activation mechanisms of the androgen receptor (AR), a key driver of cancer proliferation in prostate cells that have become resistant to traditional androgen-deprivation therapies. This evidence concerns the gene AR and cancer.